loading
전일 마감가:
$3.75
열려 있는:
$3.77
하루 거래량:
1.95M
Relative Volume:
0.42
시가총액:
$901.42M
수익:
$38.03M
순이익/손실:
$-146.40M
주가수익비율:
-7.3077
EPS:
-0.52
순현금흐름:
$-121.38M
1주 성능:
+1.60%
1개월 성능:
+64.50%
6개월 성능:
+21.41%
1년 성능:
+40.22%
1일 변동 폭
Value
$3.66
$3.81
1주일 범위
Value
$3.28
$3.81
52주 변동 폭
Value
$1.8906
$4.085

앱셀레라바이오로직스 Stock (ABCL) Company Profile

Name
명칭
Abcellera Biologics Inc
Name
전화
(604) 559-9005
Name
주소
150 W 4TH AVENUE, VANCOUVER
Name
직원
596
Name
트위터
Name
다음 수익 날짜
2024-11-18
Name
최신 SEC 제출 서류
Name
ABCL's Discussions on Twitter

ABCL을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ABCL
Abcellera Biologics Inc
3.80 901.42M 38.03M -146.40M -121.38M -0.52
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
459.62 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.36 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
331.91 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
543.48 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.49 28.51B 3.81B -644.79M -669.77M -6.24

앱셀레라바이오로직스 Stock (ABCL) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-08-20 다운그레이드 The Benchmark Company Buy → Hold
2024-02-22 업그레이드 The Benchmark Company Hold → Buy
2023-12-05 개시 KeyBanc Capital Markets Overweight
2023-11-06 다운그레이드 The Benchmark Company Buy → Hold
2023-10-13 재개 Piper Sandler Overweight
2023-02-28 개시 Cowen Outperform
2022-12-15 개시 Goldman Buy
2022-11-16 개시 Truist Buy
2021-12-21 개시 The Benchmark Company Buy
2021-11-19 개시 Piper Sandler Overweight
2021-01-05 개시 BMO Capital Markets Outperform
2021-01-05 개시 Berenberg Buy
2021-01-05 개시 Credit Suisse Outperform
2021-01-05 개시 SVB Leerink Outperform
2021-01-05 개시 Stifel Buy
모두보기

앱셀레라바이오로직스 주식(ABCL)의 최신 뉴스

pulisher
Jun 13, 2025

AbCellera shareholders approve board election and auditor - Investing.com Australia

Jun 13, 2025
pulisher
Jun 13, 2025

AbCellera shareholders approve board election and auditor By Investing.com - Investing.com Nigeria

Jun 13, 2025
pulisher
Jun 13, 2025

AbCellera Biologics Holds Annual Shareholder Meeting - TipRanks

Jun 13, 2025
pulisher
Jun 13, 2025

AbCellera Biologics: The Dilemma Of A Promising Pipeline Alongside Cash Burn (ABCL) - Seeking Alpha

Jun 13, 2025
pulisher
Jun 12, 2025

ABCELLERA BIOLG (ABCL) Upgraded to Buy: Here's Why - MSN

Jun 12, 2025
pulisher
Jun 11, 2025

AbCellera Biologics (ABCL) Stands Out in Active Option Classes | - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

AbCellera Biologics (ABCL) Stands Out in Active Option Classes | ABCL Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 09, 2025

AbCellera Biologics Inc. (ABCL): A Bull Case Theory - MSN

Jun 09, 2025
pulisher
Jun 09, 2025

Squarepoint Ops LLC Acquires 44,367 Shares of AbCellera Biologics Inc. (NASDAQ:ABCL) - Defense World

Jun 09, 2025
pulisher
Jun 03, 2025

AbCellera Biologics Inc. (ABCL) Approved to Begin ABCL575 Trial for Atopic Dermatitis - MSN

Jun 03, 2025
pulisher
Jun 03, 2025

AbCellera Biologics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance

Jun 03, 2025
pulisher
Jun 02, 2025

Why AbCellera Biologics Stock Raced Nearly 6% Higher Today - AOL.com

Jun 02, 2025
pulisher
Jun 02, 2025

AbCellera (ABCL) Stock Rises on Health Canada Approval - GuruFocus

Jun 02, 2025
pulisher
May 31, 2025

AbCellera gains Health Canada nod for AD antibody trial By Investing.com - Investing.com South Africa

May 31, 2025
pulisher
May 30, 2025

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575 - BioSpace

May 30, 2025
pulisher
May 30, 2025

AbCellera (ABCL) Gains Health Canada Approval for Clinical Trial - GuruFocus

May 30, 2025
pulisher
May 30, 2025

AbCellera Biologics Receives Health Canada Approval for Trial - TipRanks

May 30, 2025
pulisher
May 30, 2025

AbCellera Biologics Gets Health Canada Authorization for Phase 1 Trial of Dermatitis Treatment - marketscreener.com

May 30, 2025
pulisher
May 30, 2025

AbCellera Receives Authorization from Health Canada to Initiate - GuruFocus

May 30, 2025
pulisher
May 30, 2025

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575 | ABCL Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

AbCellera receives Health Canada authorization to initiate ABCL575 Phase 1 trial - TipRanks

May 30, 2025
pulisher
May 30, 2025

AbCellera gains Health Canada nod for AD antibody trial - Investing.com

May 30, 2025
pulisher
May 30, 2025

Health Canada Greenlights AbCellera's Novel Antibody Trial for Chronic Skin Disease Treatment - Stock Titan

May 30, 2025
pulisher
May 30, 2025

AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Holdings Boosted by Millennium Management LLC - Defense World

May 30, 2025
pulisher
May 30, 2025

AbCellera Biologics Inc. (ABCL): Analysts See 474% Upside Potential - MSN

May 30, 2025
pulisher
May 29, 2025

AbCellera Biologics Inc. raises US$100M in series A2 financing - McCarthy Tétrault

May 29, 2025
pulisher
May 20, 2025

13 Best Multibagger Stocks to Invest in Now - Insider Monkey

May 20, 2025
pulisher
May 18, 2025

Truist Financial Has Lowered Expectations for AbCellera Biologics (NASDAQ:ABCL) Stock Price - Defense World

May 18, 2025
pulisher
May 16, 2025

Truist cuts AbCellera stock target to $10, maintains Buy By Investing.com - Investing.com South Africa

May 16, 2025
pulisher
May 16, 2025

Truist Securities Lowers Price Target for AbCellera Biologics (A - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Truist cuts AbCellera stock target to $10, maintains Buy - Investing.com Australia

May 16, 2025
pulisher
May 16, 2025

Truist Securities Lowers Price Target for AbCellera Biologics (ABCL) | ABCL Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Truist Adjusts Price Target for AbCellera (ABCL) Amid Strategic Shift | ABCL Stock News - GuruFocus

May 16, 2025
pulisher
May 15, 2025

Abcellera gains Canadian clearance for phase I study of ABCL-635 for vasomotor symptoms in menopause - BioWorld MedTech

May 15, 2025
pulisher
May 15, 2025

Some Analysts Just Cut Their AbCellera Biologics Inc. (NASDAQ:ABCL) Estimates - simplywall.st

May 15, 2025
pulisher
May 15, 2025

Analyst Forecasts Just Became More Bearish On AbCellera Biologics Inc. (NASDAQ:ABCL) - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

AbCellera to begin Phase 1 trial for menopause treatment By Investing.com - Investing.com Nigeria

May 15, 2025
pulisher
May 14, 2025

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause - BioSpace

May 14, 2025
pulisher
May 14, 2025

AbCellera Biologics Gets Health Canada Approval for Phase 1 Trial of Menopause Treatment - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

AbCellera to begin Phase 1 trial for menopause treatment - Investing.com

May 14, 2025
pulisher
May 14, 2025

AbCellera (ABCL) Set to Launch Clinical Trial for Menopause Trea - GuruFocus

May 14, 2025
pulisher
May 14, 2025

AbCellera (ABCL) Set to Launch Clinical Trial for Menopause Treatment | ABCL Stock News - GuruFocus

May 14, 2025

앱셀레라바이오로직스 (ABCL) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.30
price down icon 0.68%
$36.37
price up icon 0.50%
$24.55
price up icon 8.53%
$97.80
price down icon 0.45%
$110.00
price up icon 1.61%
biotechnology ONC
$245.49
price up icon 0.48%
자본화:     |  볼륨(24시간):